Logo image of GLMD

GALMED PHARMACEUTICALS LTD (GLMD) Stock Fundamental Analysis

NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD

2.7031  +0.15 (+6%)

Fundamental Rating

3

Overall GLMD gets a fundamental rating of 3 out of 10. We evaluated GLMD against 571 industry peers in the Biotechnology industry. While GLMD has a great health rating, there are worries on its profitability. GLMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GLMD has reported negative net income.
In the past year GLMD has reported a negative cash flow from operations.
GLMD had negative earnings in each of the past 5 years.
GLMD had a negative operating cash flow in each of the past 5 years.
GLMD Yearly Net Income VS EBIT VS OCF VS FCFGLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.19%, GLMD is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
GLMD has a better Return On Equity (-34.30%) than 75.94% of its industry peers.
Industry RankSector Rank
ROA -30.19%
ROE -34.3%
ROIC N/A
ROA(3y)-79.39%
ROA(5y)-63.92%
ROE(3y)-96.47%
ROE(5y)-76.78%
ROIC(3y)N/A
ROIC(5y)N/A
GLMD Yearly ROA, ROE, ROICGLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

GLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLMD Yearly Profit, Operating, Gross MarginsGLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLMD has less shares outstanding
GLMD has less shares outstanding than it did 5 years ago.
GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLMD Yearly Shares OutstandingGLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
GLMD Yearly Total Debt VS Total AssetsGLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -12.41, we must say that GLMD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GLMD (-12.41) is worse than 79.32% of its industry peers.
GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.41
ROIC/WACCN/A
WACCN/A
GLMD Yearly LT Debt VS Equity VS FCFGLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

GLMD has a Current Ratio of 7.03. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
GLMD has a Current ratio of 7.03. This is in the better half of the industry: GLMD outperforms 67.20% of its industry peers.
GLMD has a Quick Ratio of 7.03. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
GLMD has a Quick ratio of 7.03. This is in the better half of the industry: GLMD outperforms 67.74% of its industry peers.
Industry RankSector Rank
Current Ratio 7.03
Quick Ratio 7.03
GLMD Yearly Current Assets VS Current LiabilitesGLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

GLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.95%, which is quite impressive.
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-878.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.64%
EPS Next 2Y40.47%
EPS Next 3Y25.44%
EPS Next 5Y14.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLMD Yearly Revenue VS EstimatesGLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
GLMD Yearly EPS VS EstimatesGLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLMD Price Earnings VS Forward Price EarningsGLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLMD Per share dataGLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30

4.3 Compensation for Growth

GLMD's earnings are expected to grow with 25.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.44%

More info and screens

0

5. Dividend

5.1 Amount

GLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (2/21/2025, 8:23:54 PM)

2.7031

+0.15 (+6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2024-11-20
Earnings (Next)04-02 2025-04-02/amc
Inst Owners3.08%
Inst Owner Change699.41%
Ins Owners1.29%
Ins Owner ChangeN/A
Market Cap4.08M
Analysts82.86
Price Target12.24 (352.81%)
Short Float %0.46%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-39.12
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-3.18
OCFYN/A
SpS0
BVpS12.21
TBVpS12.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.19%
ROE -34.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.39%
ROA(5y)-63.92%
ROE(3y)-96.47%
ROE(5y)-76.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.03
Quick Ratio 7.03
Altman-Z -12.41
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.33%
Cap/Depr(5y)30%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-878.46%
EPS Next Y96.64%
EPS Next 2Y40.47%
EPS Next 3Y25.44%
EPS Next 5Y14.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.6%
OCF growth 3YN/A
OCF growth 5YN/A